newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases,